Latest Novo Holdings A/S Stock Portfolio
Novo Holdings A/S Performance:
2024 Q3: 7.12%YTD: -1.07%2023: 31.69%
Performance for 2024 Q3 is 7.12%, and YTD is -1.07%, and 2023 is 31.69%.
About Novo Holdings A/S and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Novo Holdings A/S reported an equity portfolio of $2 Billions as of 30 Sep, 2024.
The top stock holdings of Novo Holdings A/S are VB, , . The fund has invested 14.6% of it's portfolio in VANGUARD INDEX FDS and 11.4% of portfolio in TEMPUS AI INC.
The fund managers got completely rid off APPLE INC (AAPL), MORPHIC HLDG INC (MORF) and GALECTO INC (GLTO) stocks. They significantly reduced their stock positions in IO BIOTECH INC (IOBT), SALESFORCE INC (CRM) and LEXEO THERAPEUTICS INC. Novo Holdings A/S opened new stock positions in ZENAS BIOPHARMA INC and GALECTO INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to VIRIDIAN THERAPEUTICS INC (VRDN), CELLDEX THERAPEUTICS INC NEW (CLDX) and 4D MOLECULAR THERAPEUTICS IN (FDMT).
The top stock holdings of Novo Holdings A/S are VB, , . The fund has invested 14.6% of it's portfolio in VANGUARD INDEX FDS and 11.4% of portfolio in TEMPUS AI INC.
The fund managers got completely rid off APPLE INC (AAPL), MORPHIC HLDG INC (MORF) and GALECTO INC (GLTO) stocks. They significantly reduced their stock positions in IO BIOTECH INC (IOBT), SALESFORCE INC (CRM) and LEXEO THERAPEUTICS INC. Novo Holdings A/S opened new stock positions in ZENAS BIOPHARMA INC and GALECTO INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to VIRIDIAN THERAPEUTICS INC (VRDN), CELLDEX THERAPEUTICS INC NEW (CLDX) and 4D MOLECULAR THERAPEUTICS IN (FDMT).
Novo Holdings A/S Annual Return Estimates Vs S&P 500
Our best estimate is that Novo Holdings A/S made a return of 7.12% in the last quarter. In trailing 12 months, it's portfolio return was 21.16%.
New Buys
| Ticker | $ Bought |
|---|---|
| zenas biopharma inc | 19,458,000 |
| galecto inc | 1,213,940 |
New stocks bought by Novo Holdings A/S
Additions
| Ticker | % Inc. |
|---|---|
| viridian therapeutics inc | 19.25 |
| celldex therapeutics inc new | 13.37 |
| 4d molecular therapeutics in | 7.14 |
| kyverna therapeutics inc | 5.71 |
| merus n v | 3.7 |
| arrivent biopharma inc | 0.35 |
Additions to existing portfolio by Novo Holdings A/S
Reductions
| Ticker | % Reduced |
|---|---|
| io biotech inc | -24.27 |
| salesforce inc | -23.24 |
| lexeo therapeutics inc | -22.61 |
| vaxcyte inc | -21.05 |
| edgewise therapeutics inc | -12.52 |
| brookfield corp | -10.03 |
| insmed inc | -9.42 |
Novo Holdings A/S reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| galecto inc | -1,183,950 |
| morphic hldg inc | -12,776,200 |
| apple inc | -38,535,000 |
Novo Holdings A/S got rid off the above stocks
Sector Distribution
Novo Holdings A/S has about 53.3% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 53.3 |
| Healthcare | 39.5 |
| Technology | 5.1 |
| Communication Services | 2.1 |
Market Cap. Distribution
Novo Holdings A/S has about 11% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 53.3 |
| MID-CAP | 20 |
| SMALL-CAP | 15.5 |
| LARGE-CAP | 6 |
| MEGA-CAP | 5 |
Stocks belong to which Index?
About 39.2% of the stocks held by Novo Holdings A/S either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 60.8 |
| RUSSELL 2000 | 34.2 |
| S&P 500 | 5 |
Novo Holdings A/S Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Novo Holdings A/S
Novo Holdings A/S has 37 stocks in it's portfolio. About 68.6% of the portfolio is in top 10 stocks. FDMT proved to be the most loss making stock for the portfolio. EWTX was the most profitable stock for Novo Holdings A/S last quarter.
Last Reported on: 24 Oct, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AAPL | apple inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ABCL | abcellera biologics inc | 0.15 | 1,126,920 | 2,929,980 | unchanged | 0.00 | ||
| ALNY | alnylam pharmaceuticals inc | 1.62 | 118,383 | 32,558,900 | unchanged | 0.00 | ||
| BABA | alibaba group hldg ltd | 2.64 | 500,827 | 53,147,800 | unchanged | 0.00 | ||
| BMRN | biomarin pharmaceutical inc | 1.71 | 490,000 | 34,442,100 | unchanged | 0.00 | ||
| BPMC | blueprint medicines corp | 0.80 | 175,000 | 16,187,500 | unchanged | 0.00 | ||
| CABO | cable one inc | 2.06 | 118,403 | 41,416,200 | unchanged | 0.00 | ||
| CLDX | celldex therapeutics inc new | 1.63 | 963,663 | 32,754,900 | added | 13.37 | ||
| CORT | corcept therapeutics inc | 5.54 | 2,411,360 | 111,598,000 | unchanged | 0.00 | ||
| CRM | salesforce inc | 5.01 | 368,560 | 100,879,000 | reduced | -23.24 | ||
| CRNX | crinetics pharmaceuticals in | 2.54 | 1,000,000 | 51,100,000 | unchanged | 0.00 | ||
| EWTX | edgewise therapeutics inc | 7.36 | 5,549,900 | 148,127,000 | reduced | -12.52 | ||
| FDMT | 4d molecular therapeutics in | 0.80 | 1,500,000 | 16,215,000 | added | 7.14 | ||
| FOLD | amicus therapeutics inc | 1.33 | 2,500,000 | 26,700,000 | unchanged | 0.00 | ||
| GLTO | galecto inc | 0.06 | 99,913 | 1,213,940 | new | |||
| GLTO | galecto inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| INSM | insmed inc | 2.63 | 724,666 | 52,900,600 | reduced | -9.42 | ||
| IOBT | io biotech inc | 0.17 | 3,354,450 | 3,522,170 | reduced | -24.27 | ||
| MIRM | mirum pharmaceuticals inc | 2.90 | 1,500,000 | 58,500,000 | unchanged | 0.00 | ||
| MORF | morphic hldg inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||